GlobeNewswire Inc | Jan 31, 2022 04:05PM EST

January 31, 2022

AUSTIN, Texas, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, announced today that it has entered into agreements to provide its testing services to Medicaid plan members in the state of New Hampshire and Washington, D.C equaling nearly a half million covered lives. The state of New Hampshire covers 200,000 lives and Washington D.C. covers 265,000 lives under their respective Medicaid programs. With the addition of these plans, Aspira is now credentialed to provide its OVA1 testing to nearly 80% of the Medicaid population in the U.S., totaling approximately 60 million lives.

This is another example of our steadfast commitment to ensure that the Medicaid population have equal access to our non-invasive technology for ovarian cancer risk assessment, remarked Valerie Palmieri, President and CEO of Aspira Womens Health. Our goal is to proactively pursue these plans until we have 100% of the Medicaid lives credentialed in the U.S. to ensure access for all.

About Aspira Womens Health Inc.Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1pluscombines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiXtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is working to deliver a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development include OVAWatchand EndoCheck. To improve patient accessibility, Aspira Womens Health has recently launched our Aspira Synergytechnology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. RobinsonLifeSciAdvisors, LLCTel 617-430-7577Arr@lifesciadvisors.com